ISL
EPRX

Ingalls & Snyder LLC’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ingalls & Snyder LLC’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Sell
68,450
-7,200
-10% -$49.6K 0.01% 319
2026
Q1 		$548K Sell
75,650
-1,750
-2% -$14.1K 0.02% 279
2025
Q4 		$584K Buy
77,400
+18,300
+31% +$113K 0.02% 274
2025
Q3 		$349K Buy
59,100
+21,900
+59% +$119K 0.01% 353
2025
Q2 		$214K Buy
+37,200
New +$143K 0.01% 418

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ingalls & Snyder LLC's EPRX Position: Q2 2026 in Review

Ingalls & Snyder LLC reduced its Eupraxia Pharmaceuticals (EPRX) stake by 9.5% in Q2 2026, selling an estimated $49.6K and leaving 68,450 shares worth $452K. The position accounts for 0.01% of the portfolio, ranked #319.

Ingalls & Snyder LLC first reported a position in EPRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $584K in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Ingalls & Snyder LLC held 68,450 shares of Eupraxia Pharmaceuticals worth $452K as of Q2 2026.
  • Ingalls & Snyder LLC sold 7,200 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $49.6K.
  • Eupraxia Pharmaceuticals made up 0.01% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #319 holding.
  • Ingalls & Snyder LLC first reported a position in Eupraxia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Ingalls & Snyder LLC's Eupraxia Pharmaceuticals position peaked at $584K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.